The results of phase I/II studies have shown that NeuVax, (with GM-CSF as an adjuvant), is well tolerated and is able to effectively induce HER2-specific immunity in patients with HER2-positive breast cancer, not to mention that the vaccine was proven to reduce the recurrence rate when used in an adjuvant setting. This evidence concerns the gene ERBB2 and breast carcinoma.